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Accepted 3 April 2012AbstractObjective: This paper reports the long-term follow-up (62e83 months) of women with unexplained subfertility secondary to severe adenomyosis
treated with the combination of conservative surgery and gonadotropin releasing hormone agonist (GnRH agonist) therapy.
Materials and Methods: A retrospective study included nine patients with a history of > 3 years of unexplained infertility who had extensive
uterine adenomyosis. These nine couples were diagnosed with unexplained infertility after excluding other possible causes, such as the male
factor, ovulation disorders, structural abnormality, and infections. All were essentially normal except for presumed uterine adenomyosis and
elevated serum levels of CA125. All underwent a careful excision of the adenomyosis tissue using a microsurgical technique, and then a six-
month course of GnRH agonist therapy. The outcome evaluations included serum level of CA125, degree of dysmenorrhea, and rate of
spontaneous pregnancy.
Results: Postoperative follow-up showed that the severity of dysmenorrhea was significantly improved. The improvement scale was positively
correlated with a decline in the serum level of CA125. A postoperative serum CA125 decreased to less than 10.00 IU/mL predicted well the
spontaneous pregnancy rate, especially during the therapy. In the end, only two women became pregnant and finally delivered viable babies in
this study.
Conclusions: Although the combination of careful conservative surgery and GnRH agonist therapy might provide some benefits in patients with
unexplained infertility and presumed severe adenomyosis, two-thirds of the patients still failed to become pregnant. The postoperative serum
level of CA125 could predict the future pregnancy rate.
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Uterine adenomyosis is a gynecologic condition whose
diagnosis and clinical significance remains somewhat enig-
matic [1,2]. An association between adenomyosis and infer-
tility has not been fully established [3]. Some researchers
believe that adenomyosis is not associated with subfertility,cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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multiparity, and there have been several pathology-based
studies published, in which women with adenomyosis found
at hysterectomy were often more parous than women in whom
it was not found [4,5]. By contrast, the possibility of an asso-
ciation between adenomyosis and subfertility has been raised
in a few small case series in which fertility was restored after
the successful treatment of adenomyosis with hormonal and/or
surgical therapy [6e20]. The majority of patients were treated
with gonadotropin-releasing hormone agonist (GnRH agonist)
[6e11], and some were treated with surgery only [12,13].
However, the role of surgery in managing extensive uterine
adenomyosis and subfertility is still highly controversial, partly
because the diagnosis of adenomyosis has always been retro-
spective, and adenomyosis often involves the whole uterus
diffusely, with difficulty separating normal myometrial tissue
from myometrial tissue invaded by adenomyosis [16,18].
The surgical approach for preserving the uterus has become
more popular, partly because some patients want to preserve
their future fertility, and their dysmenorrhea does not respond
to drug treatment [21]. For example, Fujishita et al used
a transverse H incision technique to successfully treat exten-
sive uterine adenomyosis [22]. In addition, a recent report
from Morita et al also showed the possible benefits of using
laparoscopic excision to manage well-defined adenomyoma,
and concluded that this approach can provide a promising
result [23], suggesting the possible benefits of the surgical
approach to deal with extensive uterine adenomyosis.
We first attempted to use combination therapy, with
medical and conservative surgical treatment, in managing
subinfertile patients with extensive uterine adenomyosis [15].
In our previous reports, we highlighted the possible benefits of
surgical attempt with/without GnRH agonist treatment for
infertile women with severe dysmenorrhea and suspicious
extensive uterine adenomyosis [16e18], and another report
also supported this approach [19]. So far, long-term follow-up
reports of this combination therapy have not been found in the
literature. In order to clarify the role and/or effectiveness of
this combination therapy for extensive uterine adenomyosis,
this report evaluated the long-term fertility outcome of these
subfertile women with unexplained infertility and presumed
severe uterine adenomyosis, who were treated with micro-
surgical complete resection of the visible adenomyotic area
followed by treatment with GnRH agonist.
Materials and methods
A total of nine women with a history of > 3 years of
infertility were included in this study. The characteristics of all
patients are summarized in Table 1. All nine patients were
classified as having unexplained infertility, because no other
possible causes of infertility were identified [24,25]. In addi-
tion, all these patients suffered from severe periodic colicky
dysmenorrhea and occasional menorrhagia [26].
All patients underwent a microsurgical technique to avoid
extensive injury to the uterus. This technique included an
initial pitressin injection, a midline incision on the anteriorwall, a meticulous coagulation, continuous irrigation with
heparin-containing warm saline, careful excision of the ade-
nomyotic tissue without damage to the uterine cavity, an
adhesion prevention barrier (oxidized regenerated cellulose,
ORC; Interceed; Johnson & Johnson Medical Inc., Arlington,
TX), and a clearing of the abdominal cavity [27]. Among the
nine women, one received a secondary operation two years
later, after complete therapy using the same strategy owing to
regrowth of the adenomyosis and exacerbation of dysmenor-
rhea, although she was treated with an intermittent course of
GnRH agonist treatment during the follow-up (Table 2).
Results
All patients received a complete six-course of GnRH
agonist therapy (3.6 mg goserelin acetate or 3.75 mg Leuprin
depot) started immediately after operation (often within 48
hours). The follow-up duration ranged from 62 months to 83
months. All patients showed significant improvement in their
symptoms or signs of dysmenorrhea or menorrhagia. For
example, the severity of pain significantly decreased from
a severe degree to a mild degree, or to an absence of pain,
during the treatment. It was striking to find three patients
(33%), who no longer complained of dysmenorrhea during the
follow-up. Five of the remaining six patients had a re-attack of
dysmenorrhea, but with less severity. Only one patient (No. 4)
suffered from severe dysmenorrhea 30 months after the initial
operation. This patient was treated with the same protocol
again at the 32nd month after the initial operation, but only
marginal improvement of her symptoms or signs was seen.
During the follow-up period, two-thirds of the patients
(n¼ 6) received various cycles of assisted reproductive tech-
niques (ART), but two of them became pregnant during the
treatment. In the end, one-third of the women attained natural
conception without the assistance of ART. Two of the 9
women delivered viable infants by a low transverse selective
Cesarean section.
In a careful review of the women who became pregnant, we
found that the postoperative serum levels of CA125 were
always within the normal limit, and that all of them showed
a serum level less than 15.00 IU/mL during therapy. In addi-
tion, the serum CA125 level of these patients was also
maintained below 35.00 IU/mL.
Discussion
The term “adenomyosis uteri” was used first by Frankl [28].
Adenomyosis is defined as a benign invasion of the endome-
trium into the myometrium, producing a diffusely enlarged
uterus, which microscopically exhibits ectopic, non-neoplastic
endometrial glands and stroma surrounded by the hypertrophic
and hyperplastic myometrium [29]. Most pathologists make
a diagnosis of adenomyosis if the glandular extension below
the endometrial myometrial interface (EMI) is greater than
2.5 mm [30]. Approximately 35% of adenomyotic cases are
asymptomatic [29]. In the remaining cases, the symptoms start
1 week prior to the menstrual flow [14]. The most frequently
Table 1
The characteristics of the patients.
Characteristics Patient
1 2 3 4a 5 6 7 8 9
Age (y) 33 34 31 35 37 37 34 35 32
Infertilityb 1 2 1 1 2 1 1 1 1
Dysmenorrhea S S S S S S S S S
Menorrhagia Y Y N Y Y Y Y Y Y
Pelvic examination: All showed
a firm and enlarged uterus
Duration of infertility (years) 4 5 4 4 5 6 6 4 3
History of therapy G G A G, AIH A G, AIH, IVF AIH, IVF AIH G, AIH, IVF
Preoperative evaluation
Semen analysisc WNL WNL WNL WNL WNL WNL WNL WNL WNL
Ovulation factord WNL WNL WNL WNL WNL WNL WNL WNL WNL
Tube/uterine factore WNL WNL WNL WNL WNL WNL WNL WNL WNL
Peritoneal factorf WNL E WNL WNL WNL WNL WNL E WNL
Cervical factorg WNL WNL WNL WNL WNL WNL WNL WNL WNL
Ultrasound size (cm) 13x 14x 11x 11x 14x 18x 13x 14x 11x
14x 18x 12x 9x 13x 15x 14x 13x 11x
15 12 9 12 14 16 11 13 10
Hormoneh WNL WNL WNL WNL WNL WNL WNL WNL WNL
CA125 (IU/mL) 106.9 164.5 89.1 115.3 196.4 145.5 69.5 292.4 143.5
Excision tissue (g) 240 420 120 105 280 190 195 345 90
Postoperative evaluation
Postoperative follow-up (mo) 64 72 83 62 67 65 66 68 62
G therapy P P P P P P P P P
Uterine size, 3M 9x 8x 8x 8x 8x 9x 8x 7x 7x
8x 6x 8x 6x 7x 7x 5x 6x 7x
9 5 7 8 8 6 7 6 6
Uterine size, 12 M 10x 8x NA 9x 8x 12x 9x 7x 9x
10x 9x 8x 6x 10x 8x 7x 7x
7 6 9 5 8 6 5 6
CA125 (IU/mL) 3 M 14.8 15.5 12.2 15.6 9.6 12.1 17.2 7.8 13.4
CA125 (IU/ml) 12 M 67.6 49.6 NA 102.4 12.5 54.3 29.1 11.2 41.9
HSG 4 M WNL WNL WNL WNL WNL WNL WNL WNL WNL
Spontaneous pregnancy A A A A P A P P A
ART A P P A P P P P A
Successful delivery of baby A A A A P A A P A
A¼ absence; AIH¼ artificial insemination from her husband; ART¼assisted reproductive techniques, including AIH or IVF; E¼ extra-uterine endometriosis;
G¼GnRH agonist treatment; HSG¼ hysterosalpingography; IVF¼ in-vitro fertilization and embryo transplantation; M¼months; NA¼ no data available;
P¼ presence; S¼ severe; WNL¼within the normal limits.
a This patient underwent cytoreductive surgery twice.
b 1 refers to primary infertility and 2 refers to secondary infertility.
c The evaluation of male factor infertility was based on the normal values suggested by the world Health Organization (WHO), including volume < 2.0 mL;
sperm concentration < 20 million/mL; motility < 50%; morphology < 30% normal forms.
d Documentation of ovulation included basal body temperature, midluteal serum progesterone, LH surge, ultrasound monitoring, and endometrial biopsy.
e Based on hysterosalpingography, a normal contour of the uterine cavity and patency of bilateral tubes were found.
f Based on laparoscopic examination, no paratubal adhesion, no extrauterine endometriosis and only an enlarged, firm uterus were found.
g Normal cervical mucusesperm interaction.
h Hormone survey included serum prolatin level, thyroid-stimulating hormone, FSH, DHEAS, DHEA and testosterone level.
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(50%), secondary dysmenorrhea (30%), and an enlarged,
tender uterus [3]. The dysmenorrhea pattern often presents as
cramps and colic pain, with a heavy amount of blood during
menstruation, and also nightmares for these patients. In
addition to dysmenorrhea, more than two-thirds of the patients
in this study also suffered from menorrhagia. Adenomyosis of
the uterus is often described as scattered, widely distributed
endometrial glands or stromal tissue throughout the myome-
trium layer of the uterus. Sometimes, adenomyosis can form
a mass lesion within the myometrium, often called an ade-
nomyoma [18,31].The relation between infertility and uterine adenomyosis is
still uncertain, but severe endometriosis indeed impairs the
successful pregnancy rate during the artificial ART. To date,
there is no uniform agreement on the most appropriate ther-
apeutic methods for managing the uterine adenomyosis
[16e18], partly because the diagnosis of adenomyosis has
always been retrospective, and only a surgical approach can
identify it correctly. Recent reports highly recommend that
high-resolution magnetic resonance imaging and/or ultrasound
may offer a relatively more accurate predicted value in the
diagnosis or localization of adenomyosis and/or adenomyoma
[32,33].
Table 2
Summary of nine patients with adenomyosis treated with conservative surgery and GnRH agonist.
Baseline (M  SD) 3 months (M  SD) 12 months (M  SD) p1a p2a Remarks
UT volume 1196  543 194  68 264  130 0.0006 0.0006
CA125 147.0  67.0 13.1  3.0 46.1  30.2 0.0004 0.0009
Pain score 4.7  0.5 0.33  0.5 1  0.9 0.000 0.000
Satisfaction 1  0 3  0 2.8  0.4 0.000 0.000
Spontaneous pregnancy 3/9, 33.3%
ART 6/9, 66.7%
Successful delivery 2/9, 22.2%
ART¼assisted reproductive techniques; M¼mean; p1¼ difference between baseline and 3 months; p2¼ difference between baseline and 12 months;
SD¼ standard deviation; UT¼ uterine.
a Student t test was used for analyzing the difference between the two groups.
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a reduced myoma size [34e36] and possibly suppressing
endometriosis [37e39]. This strategy has resulted in a few
case reports of successful pregnancy and delivery, but its effect
is often transient, and is often used with a preoperative adju-
vant therapy. Surgical intervention is seldom considered to
play a role in managing such patients. The most important
consideration is the difficulty of selecting a good candidate to
undergo this surgical approach; because, how do you deter-
mine the extent of adenomyosis in a particular patient?
Furthermore, adenomyosis is not cleared completely by
conservative surgery. In addition, postoperative sequels, such
as pelvic adhesion, cannot be completely avoided [40].
Finally, the rupture of a pregnant uterus has been observed
after myomectomy [41e44]. In this study, the age of the all
patients was > 30 years, and the duration of infertility was
more than 36 months; as such, these were not good candidates
to receive expectant management [3,4]. Menorrhagia is also
a symptom presenting, and this constitutes a definite indication
for operation [5]. The patients in this study also suffered from
increasing dysmenorrhea, which subsequently impaired them
from performing their daily work, due to a huge and firm
uterus. In the end, the probability of a spontaneous pregnancy
was not great, even though GnRH agonist was used to treat
these patients. Two patients underwent a variable course of
GnRH agonist treatment, but to no effect. Considering all the
above-mentioned reasons, there seemed to be a strong ratio-
nale supporting the use of surgery.
The beneficial role of the combination of cytoreductive
surgery and GnRH agonist treatment in managing infertile
women with adenomyosis could include the removal of
a tumor with a relatively poor blood supply, and the
enhancement of the immune function of the host, which can
result in enhancing the response of the remaining tumor to
chemotherapy. In addition, the huge size of uterine myoma
and uneven distribution of medication could explain why the
variability in the response among individuals treated with
GnRH agonist to reductions of uterine myoma volume is so
great. The serum marker CA125 is useful for long-term
screening and/or monitoring of endometriosis [45]. Yen et al
also suggested that the CA125 level may be a valuable indi-
cator for monitoring the efficacy of laparoscopic bipolar
coagulation of the uterine vessels for symptomatic myomas inwomen with elevated CA125 [46]. In this study, we also found
that the serum CA125 level is a good indicator for monitoring
the efficacy of the combination of conservative surgery and
GnRH agonist therapy for symptomatic adenomyosis in
women with subfertility. In agreement with the above finding,
the severity of dysmenorrhea is also negatively correlated with
the serum CA125 level, suggesting that part, if not all, of
tumor (adenomyosis) behavior may also involve the disease
progression during therapy; however, we cannot provide
evidence to support this hypothesis.
In conclusion, this report further supports the concept that
the combination of microsurgical cytoreduction and GnRH
agonist treatment could be appropriate in patients who have
failed GnRH agonist treatment alone or who do not have
tolerance of long-term GnRH agonist treatment, with presumed
severe adenomyosis, such as a huge and firm uterus, severe
dysmenorrhagia, and clinically unexplained subfertility. The
postoperative serum level of CA125, either three months or 12
months later, could predict the outcome of these patients,
including the restoration of fertility and improvement of
dysmenorrhea. Since two-thirds of the patients did not become
pregnant, and some patients had recurrent dysmenorrhea, we do
not think this strategy should be routine in managing woman
with presumed adenomyosis, partly because the diagnosis of
adenomyosis has always been retrospective, partly because the
use of GnRH agonist can be effective, and partly because of the
long-term effect (more than 10 years) is unknown.
Acknowledgments
This work was supported in part by grants from Taipei
Veterans General Hospital (V99C1-085, V100C-054,
V101C1-128, V101E4-004, V101E5-006), the TVGH-NTUH
Joint Research Program (96VN-008, 97VN-012, 98VN-015),
Veterans General Hospitals University System of Taiwan Joint
Research Program (VGHUST99-G4), and the National
Science Council (NSC 99-2314-B-010-009-MY3), Taiwan.
References
[1] Barrier BF, Malinowski MJ, Dick Jr EJ, Hubbard GB, Bates GW. Ade-
nomyosis in the baboon is associated with primary infertility. Fertil Steril
2004;82(Suppl. 3):1091e4.
216 B.-S. Huang et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 212e216[2] Levgur M. Diagnosis of adenomyosis: a review. J Reprod Med 2007;52:
177e93.
[3] Matalliotakis IM, Katsikis IK, Panidis DK. Adenomyosis: what is the
impact on fertility? Curr Opin Obstet Gynecol 2005;17:261e4.
[4] Wang PH, Su WH, Sheu BC, Liu WM. Adenomyosis and its variance:
adenomyoma and female fertility. Taiwan J Obstet Gynecol 2009;48:
232e8.
[5] Siegler AM. Adenomyosis. J Reprod Med 1994;39:841e53.
[6] Honore LH, Cumming DC, Dunlop DL, Scott JZ. Uterine adenomyoma
associated with infertility. A report of three cases. J Reprod Med 1988;
33:331e5.
[7] Huang FJ, Kung FT, Chang SY, Hsu TY. Effects of short-course buserelin
therapy on adenomyosis. A report of two cases. J Reprod Med 1999;44:
741e4.
[8] Hirata JD, Moghissi KS, Ginsburg KA. Pregnancy after medical therapy
of adenomyosis with gonadotropin-releasing hormone agonist. Fertil
Steril 1993;59:444e5.
[9] Silva PD, Perkins HE, Schauberger CW. Live birth after treatment of
severe adenomyosis with a gonadotropin-releasing hormone agonist.
Fertil Steril 1994;61:171e2.
[10] Nelson JR, Corson SL. Long-term management of adenomyosis with
a gonadotropin-releasing hormone agonist: a case report. Fertil Steril
1993;59:441e3.
[11] Lin J, Sun C, Zheng H. Gonadotropin-releasing hormone agonists and
laparoscopy in the treatment of adenomyosis with infertility. Chin Med J
(Engl) 2000;113:442e5.
[12] Liu X, Huang H, Huang R, Lian L, Lang J. Clinical observation of
conservative surgery for adenomyosis. Zhongguo Yi Xue Ke Xue Yuan
Xue Bao 1998;20:440e4 [In Chinese].
[13] Wood C, Maher P, Hill D. Biopsy diagnosis and conservative surgical
treatment of adenomyosis. Aust N Z J Obstet Gynaecol 1993;33:319e21.
[14] Devlieger R, D’Hooghe T, Timmerman D. Uterine adenomyosis in the
infertility clinic. Hum Reprod Update 2003;9:139e47.
[15] Huang WH, Yang TZ, Yuan CC. Successful pregnancy after treatment of
deep adenomyosis with cytoreductive surgery and subsequent
gonadotropin-releasing hormone agonist: A case report. Chin Med J
(Taipei) 1998;61:726e9.
[16] Wang PH, Yang TS, Lee WL, Chao HT, Chang SP, Yuan CC. Treatment
of infertile women with adenomyosis with a conservative microsurgical
technique and a gonadotropin-releasing hormone agonist. Fertil Steril
2000;73:1061e2.
[17] Wang PH, Fuh JL, Chao HT, Liu WM, Cheng MH, Chao KC. Is the
surgical approach beneficial to subfertile women with symptomatic
extensive adenomyosis? J Obstet Gynaecol Res 2009;35:495e502.
[18] Wang PH, LiuWM, Fuh JL, ChengMH, Chao HT. Comparison of surgery
alone and combined surgical-medical treatment in the management of
symptomatic uterine adenomyoma. Fertil Steril 2009;92:876e85.
[19] Ozaki T, Takahashi K, Okada M, Kurioka H, Miyazaki K. Live birth after
conservative surgery for severe adenomyosis following magnetic reso-
nance imaging and gonadotropin-releasing hormone agonist therapy. Int J
Fertil Women Med 1999;44:260e4.
[20] Yen MS, Yang TZ, Yu KJ, Wang PH. Comments on laparoscopic exci-
sion of myometrial adenomyomas in patient with adenomyosis uteri and
main symptoms of severe dysmenorrheal and hypermenorrhea. J Am
Assoc Gynecol Laparosc 2004;11:441e2.
[21] Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod
Update 1998;4:323e36.
[22] Fujishita A, Masuzaki H, Khan KN, Kitajima M, Ishimaru T. Modified
reduction surgery for adenomyosis. A preliminary report of the trans-
verse H incision technique. Gynecol Obstet Invest 2004;57:132e8.
[23] Morita M, Asakawa Y, Nakakuma M, Kubo H. Laparoscopic excision of
myometrial adenomyomas in patient with adenomyosis uteri and main
symptoms of severe dysmenorrhea and hypermenorrhea. J Am Assoc
Gynecol Laparosc 2004;11:86e9.
[24] Forti G, Krausz C. Clinical review 100: evaluation and treatment of the
infertile couple. J Clin Endocrionol Metab 1998;83:4177e88.[25] Lee WL, Liu WM, Fuh JL, Tsai YC, Shih CC, Wang PH. Basal follicle-
stimulating hormone level changes after different types of uterine vessel
occlusion in the management of uterine fibroids. Fertil Steril 2010;94:
2286e90.
[26] Lee WL, Liu WM, Fuh JL, Tsai YC, Shih CC, Wang PH. Use of uterine
vessel occlusion in the management of uterine myomas: two different
approaches. Fertil Steril 2010;94:1875e81.
[27] WenKC, ChenYJ, SungBL,Wang PH. Comparing uterine fibroids treated
by myomectomy through traditional laparotomy (LT) and two modified
approaches: ultraminilaparotomy (UMLT) and laparoscopically-assisted
ultraminilaparotomy (LA-UMLT). Am J Obstet Gynecol 2010;202. 144.
e1e144.e8.
[28] Frankl O. Adenomyosis uteri. Am J Obstet Gynecol 1925;10:680e4.
[29] Bird CC, McElin TW, Manalo-Eslrella P. The elusive adenomyosis of the
uterus. Am J Obstet Gynecol 1972;112:583e93.
[30] Uduwela AS, Perera MD, Aiqing L, Fraser IS. Endometrial-myometrial
interface: relationship to adenomyosis and changes in pregnancy. Obstet
Gynecol Survey 2000;55:390e400.
[31] Yang MH, Wang PH, Wang SJ, Sun WZ, Oyang YJ, Fuh JL. Women with
endometriosis are more likely to suffer from migraines: A population-
based study. PLoS One 2012;7:e33941.
[32] Ascher SM, Jha RC, Reinhold C. Benign myometrial conditions: leio-
myomas and adenomyosis. Top Magn Reson Imaging 2003;14:281e304.
[33] Tamai K, Koyama T, Umeoka S, Saga T, Fujii S, Togashi K. Spectrum of
MR features in adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;
20:583e602.
[34] Wang PH, Lee WL, Cheng MH, Yen MS, Chao KC, Chao HT. Use of
a gonadotropin-releasing hormone agonist to manage perimenopausal
women with symptomatic uterine myomas. Taiwan J Obstet Gynecol
2009;48:133e7.
[35] Tsai HW, Chen YJ, Ho CM, Hseu SS, Chao KC, Tsai SK, et al. Maneuvers
to decrease laparoscopy-induced shoulder and upper abdominal pain:
a randomized controlled study. Arch Surgery 2011;146:1360e6.
[36] McCarthy-Keith DM, Malik M, Britten J, Segars J, Catherino WH.
Gonadotropin-releasing hormone agonist increases expression of osmotic
response genes in leiomyoma cells. Fertil Steril 2011;95:2383e7.
[37] Lee SL, Chang CY, Chen PH, Lu CH, Chang CC. A cumulative strategy
of GnRH agonist, clomiphene citrate, and GnRH antagonist in a patient
with recurrent endometriosis and repeated aspiration. Taiwan J Obstet
Gynecol 2011;50:366e9.
[38] Fang FY, Huang BS, Chao HT, Wang PH. Ruptured ovarian endome-
trioma. Taiwan J Obstet Gynecol 2012;51:145.
[39] Huang YH, Liou JD, Hsieh CL, Shiau CS, Lo LM, Chang MY. Long-
term follow-up of patients surgically treated for ruptured ovarian endo-
metriotic cysts. Taiwan J Obstet Gynecol 2011;50:306e11.
[40] Chang WC, Hsieh CH, Lin CC, Lin WC, Hung YC, We WC. An analysis
of risk factors for postoperative pelvic cellulitis after laparoscopic-
assisted vaginal hysterectomy. Taiwan J Obstet Gynecol 2011;50:463e7.
[41] Vercellini P, Maddalena S, De Giorgi O, Aimi G, Crosignani PG.
Abdominal myomectomy for infertility: a comprehensive review. Hum
Reprod 1998;13:873e9.
[42] Yen MS, Chao KC, Wang PH. Laparoscopic myomectomy. Taiwan J
Obstet Gynecol 2010;49:392e3.
[43] Su H, Hand CM, Wang CJ, Lee CL, Soong YK. Comparison of the
efficacy of the pulsed bipolar system and conventional electrosurgery in
laparoscopic myomectomy- A retrospective matched control study.
Taiwan J Obstet Gynecol 2011;50:25e8.
[44] Horng HC, Wen KC, Su WH, Chen CS, Wang PH. Review of myo-
mectomy. Taiwan J Obstet Gynecol 2012;51:7e11.
[45] Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M,
Kitaoka Y, et al. Usefulness and limits of CA-125 in diagnosis of
endometriosis without associated ovarian endometriomas. Hum Reprod
2005;20:1999e2003.
[46] Yen YK, Liu WM, Yuan CC, Ng HT. Laparoscopic bipolar coagulation
of uterine vessels to treat symptomatic myomas in women with elevated
CA125. J Am Assoc Gynecol Laparosc 2001;8:241e6.
